Risk-sharing In The Pharmaceutical Industry: The Case Of Out-licensing by Gerrit ReepmeyerRisk-sharing In The Pharmaceutical Industry: The Case Of Out-licensing by Gerrit Reepmeyer

Risk-sharing In The Pharmaceutical Industry: The Case Of Out-licensing

byGerrit Reepmeyer

Paperback | December 5, 2005

Pricing and Purchase Info

$199.43 online 
$234.95 list price save 15%
Earn 997 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R and D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R and D managers with recommendations on how to conclude and manage this type of deals more effectively.
Title:Risk-sharing In The Pharmaceutical Industry: The Case Of Out-licensingFormat:PaperbackDimensions:297 pagesPublished:December 5, 2005Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3790816671

ISBN - 13:9783790816679

Look for similar items by category:

Reviews

Table of Contents

Introduction.- Key Issues in Managing Pharmaceutical Innovation.- Risk-sharing as New Paradigm in Pharma R and D Collaborations.- Case Studies in Risk-sharing in Pharma R and D Collaborations.- Characteristics of Risk-sharing in Pharma R and D Collaborations.- Theoretical Basis for Risk-sharing in Pharma R and D Collaborations.- Managerial Recommendations for Risk-sharing in Pharma R and D Collaborations.- Conclusion.